Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 7;15(4):1041.
doi: 10.3390/cancers15041041.

Soluble Hemojuvelin and Ferritin: Potential Prognostic Markers in Pediatric Hematopoietic Cell Transplantation

Jan Styczyński  1 , Artur Słomka  2 , Monika Łęcka  1 , Katarzyna Albrecht  3 , Michał Romiszewski  3 , Monika Pogorzała  1 , Małgorzata Kubicka  1 , Beata Kuryło-Rafińska  1 , Barbara Tejza  1 , Grażyna Gadomska  2 , Ewelina Kolańska-Dams  2 , Małgorzata Michalska  2 , Ewa Żekanowska  2
Affiliations

Soluble Hemojuvelin and Ferritin: Potential Prognostic Markers in Pediatric Hematopoietic Cell Transplantation

Jan Styczyński et al. Cancers (Basel). .

Abstract

Objective: Iron overload (IO) is a common and life-threatening complication resulting from the therapy of AL and HCT patients. This study aimed to evaluate the prognostic value of 12 serum biomarkers of iron metabolism in pediatric patients treated for AL or undergoing HCT.

Patients: Overall, 50 patients with AL after intensive treatment and 32 patients after HCT were prospectively included in the study. AL patients at diagnosis and healthy controls served as reference groups.

Methods: The impact of the following 12 serum iron metabolism parameters on the outcome of AL/HCT patients was analyzed: iron, transferrin (Tf), total iron-binding capacity (TIBC), ferritin, ferritin heavy chains (FTH1), ferritin light chains (FTL), hepcidin, soluble hemojuvelin (sHJV), soluble ferroportin-1 (sFPN1), erythroferrone (ERFE), erythropoietin (EPO), and soluble transferrin receptor (sTfR).

Results: With a median follow-up of 2.2 years, high levels of ferritin and low levels of sHJV had an adverse prognostic impact on OS and EFS in children after HCT. If these patients were combined with those with AL after intensive chemotherapy, the results were confirmed for OS and EFS both for ferritin and sHJV.

Conclusions: Among the 12 analyzed serum parameters of iron metabolism, increased levels of ferritin and decreased levels of sHJV had an adverse prognostic impact on survival in children after HCT. More data are needed to clarify the relationship between ferritin, sHJV, and mortality of AL children after intensive chemotherapy, and more extensive prospective studies are required to prove sHJV predictivity.

Keywords: acute leukemia; children; ferritin; hematopoietic cell transplantation; hemojuvelin; iron metabolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overall survival (OS) for patients after HCT (A,C,E) and patients after HCT combined with those with AL after chemotherapy (B,D,F) concerning serum levels of ferritin and sHJV levels and ferritin/sHJV ratio.
Figure 2
Figure 2
Event-free survival (EFS) for patients after HCT (A,C,E) and patients after HCT combined with those with AL (B,D,F) concerning serum levels of ferritin and sHJV levels and ferritin/sHJV ratio.
See this image and copyright information in PMC

References

    1. Ward E., DeSantis C., Robbins A., Kohler B., Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J. Clin. 2014;64:83–103. doi: 10.3322/caac.21219. - DOI - PubMed
    1. Inaba H., Pui C.H. Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. J. Clin. Med. 2021;10:1926. doi: 10.3390/jcm10091926. - DOI - PMC - PubMed
    1. Butler E., Ludwig K., Pacenta H.L., Klesse L.J., Watt T.C., Laetsch T.W. Recent progress in the treatment of cancer in children. CA Cancer J. Clin. 2021;71:315–332. doi: 10.3322/caac.21665. - DOI - PubMed
    1. Reinhardt D., Antoniou E., Waack K. Pediatric Acute Myeloid Leukemia-Past, Present, and Future. J. Clin. Med. 2022;11:504. doi: 10.3390/jcm11030504. - DOI - PMC - PubMed
    1. Duarte R.F., Labopin M., Bader P., Basak G.W., Bonini C., Chabannon C., Corbacioglu S., Dreger P., Dufour C., Gennery A.R., et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2019. Bone Marrow Transplant. 2019;54:1525–1552. doi: 10.1038/s41409-019-0516-2. - DOI - PubMed